A preprint review suggests that post vaccination, there may be nonspecific effects (NSEs) to the immune system that increase the risk of infections unrelated to the targeted disease. Vaccines that do not contain a live or weakened pathogen are called non-live vaccines and were linked to more negative NSEs, potentially increasing susceptibility to other infections, especially in girls. 

According to Children’s Health Defense: 

“For example, girls receiving the non-live DTP vaccine died at twice the rate of unvaccinated girls according to one study, with a comparable disadvantage to vaccinated boys.”

22 January 2024

The Productivity Commission’s misuse of public funds

Robert MacCulloch says the new government has disestablished the Productivity Commission because it hasn’t lived up to its name, which is to make NZ more productive and increase GDP. Instead, the commission’s reports started to emphasise issues related to fairness, disadvantage, and social inclusion. 

20 January 2024

A growing tide is challenging radical gender ideology in schools

Resisting Gender Education comments on a growing tide of caution and common sense challenging radical gender ideology. England recently released draft guidance for schools on handling gender-questioning children, emphasising parental consultation and caution in social transition.

17 January 2024

Big questions on how government temperature “adjustments” suggest a cooling climate 

In “Man-made cooling”, the findings of a recent investigation by archivist Tony Heller suggest that US government scientists have consistently adjusted historical temperature readings downwards. The further back in time, the further down the temperature adjustment. 

17 January 2024

Pharmac’s secrecy warps debate on NZ’s drug funding

In his recent article, writer Graham Adams highlights the mounting pressure on Pharmac, New Zealand’s drug procurement agency, to fund vital medications. This situation is made worse by a lack of transparency in drug pricing. Pharmac’s reluctance to reveal the rebates it receives on funded drugs, citing commercial sensitivity, distorts perceptions of drug costs.